Key result
Intravenous administration of angiogenesis-targeted nanoparticles delivering rosiglitazone or PGE2 analog inhibited body weight gain and modulated cholesterol, triglyceride, and insulin in obese mice.
Why the study?
Does targeted nanoparticle delivery of rosiglitazone or PGE2 analog prevent body weight gain and modulate metabolic markers in diet-induced obese mice?
Does targeted nanoparticle delivery of rosiglitazone or PGE2 analog prevent body weight gain and modulate metabolic markers in diet-induced obese mice?
Targeted nanoparticle delivery of angiogenic stimulators to adipose tissue vasculature inhibits weight gain and improves metabolic markers in a diet-induced obese mouse model.
Answers are grounded in this paper and cite their sources.
No immediate clinical implications; hypothesis-generating for adipose-targeted nanoparticles in metabolic disease.
The incidence of obesity, which is recognized by the American Medical Association as a disease, has nearly doubled since 1980, and obesity-related comorbidities have become a major threat to human health. Given that adipose tissue expansion and transformation require active growth of new blood vasculature, angiogenesis offers a potential target for the treatment of obesity-associated disorders. Here we construct two peptide-functionalized nanoparticle (NP) platforms to deliver either Peroxisome Proliferator-Activated Receptor gamma (PPARgamma) activator rosiglitazone (Rosi) or prostaglandin E2 analog (16,16-dimethyl PGE2) to adipose tissue vasculature. These NPs were engineered through self-assembly of a biodegradable triblock polymer composed of end-to-end linkages between poly(lactic-coglycolic acid)-b-poly(ethylene glycol) (PLGA-b-PEG) and an endothelial-targeted peptide. In this system, released Rosi promotes both transformation of white adipose tissue (WAT) into brown-like adipose tissue and angiogenesis, which facilitates the homing of targeted NPs to adipose angiogenic vessels, thereby amplifying their delivery. We show that i.v. administration of these NPs can target WAT vasculature, stimulate the angiogenesis that is required for the transformation of adipose tissue, and transform WAT into brown-like adipose tissue, by the up-regulation of angiogenesis and brown adipose tissue markers. In a diet-induced obese mouse model, these angiogenesis-targeted NPs have inhibited body weight gain and modulated several serological markers including cholesterol, triglyceride, and insulin, compared with the control group. These findings suggest that angiogenesis-targeting moieties with angiogenic stimulator-loaded NPs could be incorporated into effective therapeutic regimens for clinical treatment of obesity and other metabolic diseases.
No takes yet. Share an insight, caveat, or question.
Xue et al. (2016) studied Diet-induced obesity. Peptide-functionalized nanoparticles delivering rosiglitazone or prostaglandin E2 analog vs. Control group was evaluated on Body weight gain and serological markers (cholesterol, triglyceride, and insulin). Intravenous administration of angiogenesis-targeted nanoparticles delivering rosiglitazone or PGE2 analog inhibited body weight gain and modulated cholesterol, triglyceride, and insulin in obese mice.
Synapse has enriched 10 related papers. Consider them for comparative context: